Pharmigene, Inc. (TPEX:7595)
Taiwan · Delayed Price · Currency is TWD 9.74
-0.11 (-1.12%)
At close: May 8, 2026
Pharmigene Revenue
In the year 2025, Pharmigene had annual revenue of 199.89M TWD with 71.53% growth. Pharmigene had revenue of 80.68M in the half year ending June 30, 2025, with 50.57% growth.
Revenue
199.89M
Revenue Growth
+71.53%
P/S Ratio
2.46
Revenue / Employee
n/a
Employees
n/a
Market Cap
491.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 199.89M | 83.36M | 71.53% |
| Dec 31, 2024 | 116.53M | -16.17M | -12.19% |
| Dec 31, 2023 | 132.71M | -1.09M | -0.82% |
| Dec 31, 2022 | 133.80M | 4.45M | 3.44% |
| Dec 31, 2021 | 129.35M | 28.00M | 27.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.24B |
| DIVA Laboratories | 884.63M |
| Genetics Generation Advancement | 603.11M |
| Kim Forest Enterprise | 549.14M |
| Sofiva Genomics | 385.71M |
| Welgene Biotech | 375.94M |
| Puriblood Medical | 82.34M |